Platelet activation and aggregation profile in prolonged external ventricular support  by Houël, Rémi et al.
Houe¨l et al Cardiopulmonary Support and Physiology
CS








aDaniel Y. Loisance, MDFrom the Service de chirurgie cardiaque,
Hoˆpital Henri Mondor,a Cre´teil, France,
Unite´, Association Claude Bernard and Ser-
vice d’he´matologie biologique, Hoˆpital
Lariboisie`re,b Paris, France.
Received for publication July 28, 2003; re-
visions received Oct 20, 2003; accepted for
publication Nov 17, 2003.
Address for reprints: Re´mi Houe¨l, Institut
Jacques Cartier, Adult Cardiac Surgery, 6
Avenue du Noyer Lambert, Massy 91300,
France (E-mail: remihouel@hotmail.com).
J Thorac Cardiovasc Surg 2004;128:197-202
0022-5223/$30.00
Copyright © 2003 by The American Associ-
ation for Thoracic Surgery
doi:10.1016/j.jtcvs.2003.11.059Background: Platelet function plays a major role in the understanding of thrombo-
embolic events in prolonged mechanical support. We studied the platelet activation,
platelet aggregation profile, and efficacy of aspirin in patients in whom an external
ventricular assist device had been implanted.
Patients and Methods: Fifteen patients were studied prospectively up to 6 weeks
after implantation of the same type of ventricular assist device. Platelet function was
studied weekly before daily aspirin administration. Aspirin efficacy was tested ex
vivo by measuring platelet aggregation triggered by arachidonic acid. Flow cytom-
etry was used to quantify the spontaneous and induced (adenosine diphosphate
stimulation) expression of glycoproteins IIb3, Ib, and CD62P on platelet
membranes. The plasma levels of von Willebrand factor (von Willebrand factor
activity and von Willebrand factor antigen) and fibrinogen were also determined.
Results: Six of the 15 patients (26%) maintained an arachidonic acid-induced
platelet aggregation despite daily aspirin treatment (250 mg). CD62P values re-
mained increased during a 5-week postoperative period. Spontaneous levels of
glycoproteins IIb3 and Ib on platelet membranes remained within a normal
range with a preserved reactivity. The plasma levels of fibrinogen and von Wille-
brand factor remained increased during the entire study period.
Conclusion: In patients with an implanted external ventricular assist device, the
platelet activation profile displays a persistent activation with a preserved reactivity
associated with a persistent high inflammatory state and endothelial activation.
In patients with an external ventricular assist device (VAD), anticoagulationprotocols, such as heparin or antivitamin K anticoagulation, are usuallyassociated with at least 1 antiplatelet agent. Aspirin is the most frequentlyused antiplatelet agent despite its individual variable effect on ex vivo andin vivo platelet aggregation.1,2 Some resistance to aspirin has been observedrecently with the use of low doses of aspirin in patients with atherosclerosis
or after cardiopulmonary bypass (CPB) in coronary artery bypass grafting.3,4 The
explanation for this so-called resistance to aspirin is multiple: (1) an increased
platelet turnover after CPB, (2) cyclooxygenase-2 induction associated with an
inflammatory state, and (3) other sources of thromboxane A2 production insensitive
to aspirin.3-5 However, our knowledge on platelet function in patients with an
implanted VAD remains limited.
Platelet activation is best tested by a flow cytometry technique that measures the
expression of integrins on the platelet membrane surface.6,7 Integrins IIb3 and
Ib seem to play a key role in platelet activation and thrombus formation. Integrin
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CSPIIb3 is the last final common pathway of platelet aggre-
gation through its binding to fibrinogen or von Willebrand
factor.8 Integrin Ib mediates platelet activation and adhe-
sion through its binding to von Willebrand factor on the
subendothelium, especially in high shear stress flowing con-
ditions.9
The clinical development of VAD has brought some
changes in hemodynamic biomaterials or conduits to reduce
the incidence of device-related thromboembolic events.
These improvements could also be explained by a more
favorable host response to biomaterial implantation.10
These results may also illustrate different patterns of host
response to different devices in which surface texture and
hemodynamic conditions are different.11 The experience
gained during the last decade in mechanical support allows
studies on homogenous populations with a single type of
support and prolonged support time.
This report studies (1) the platelet activation and aggre-
gation profile of patients with a single type of external VAD




Fifteen patients were studied prospectively during a 6-week period
after implantation of the same type of external VAD (Thoratec
Corporation, Pleasanton, Calif).
The indications for emergency device implantation were the
following: persistent primary cardiogenic shock complicating
acute myocardial infarction (7 patients), acute myocarditis (2 pa-
tients), and end-stage dilated cardiomyopathy (6 patients). Seven
of the 15 patients were supported by an intra-aortic balloon pump
before device implantation.
Surgical Technique and Anticoagulation Protocol
Implantation was performed in a standard technique with CPB and
moderate hypothermia. The left inflow cannula was implanted
through the left ventricular apex in all instances. The right inflow
cannula was implanted through the right atrium in all cases except
2 (into the right ventricle). The device was run in a fill-to-empty
mode in all instances and as soon as possible (within hours
postoperatively) on the left side. On the right side, the device was
run in a fill-to-empty mode but could be on a fixed mode because
of insufficient filling (postoperatively) or right ventricular recov-
ery.
After surgery, anticoagulation was started within 8 to 12 hours
using intravenous heparin to achieve an anti-Xa activity between
0.3 and 0.4 IU/L. Aspirin was started 24 hours after surgery at a
daily dose of 250 mg. Aspirin doses were then increased gradually
from 250 mg to 350 mg when ex vivo platelet function tests
showed a persistent aggregation in the presence of arachidonic
acid (AA) and finally up to 500 mg per day if ex vivo aggregation
persisted after the previous increased dosage. In case of active
bleeding with no obvious surgical source or neurologic bleeding
complication, aspirin administration was stopped. Antivitamin K
therapy was started after removal of all chest drains and extubation
198 The Journal of Thoracic and Cardiovascular Surgery ● Auguto maintain the international normalized ratio between 3 and 4.
Fresh blood was collected for platelet function studies and cyto-
metric analysis was performed weekly from the week of implan-
tation and before daily aspirin administration. Blood was collected
from a peripheral vein using a Vacutainer system (Becton Dick-
inson, Franklin Lakes, NJ) (as for control patients) and immedi-
ately stored in ice for transport to the laboratory. The dosage of
von Willebrand factor, plasmatic fibrinogen levels, and platelet
count were determined in the same conditions.
Resistance to Aspirin
A resistance to aspirin treatment was defined by any persistent ex
vivo platelet aggregation induced by AA despite a daily adminis-
tration of aspirin.
The platelet count was determined on an ethylenediaminetet-
raacetic acid blood sample using an STKS counter (Beckman
Coulter France, Paris, France).
Platelet Aggregation
The citrated blood sample was centrifuged at 200g for 10 minutes
at room temperature. Platelet-rich plasma (PRP) was separated,
and platelet aggregation was monitored by the turbidimetric
method on a Chronolog Aggregometer (Beckman Coulter). PRP
was stirred at 37°C for 1 minute under constant agitation (1000
rpm) and aggregation was induced by the addition of AA (0.2
mg/mL final concentration, Sigma, Lyon, France). Velocity and
maximal intensity were recorded, and the results are expressed as
the percentage of aggregation.
The plasma fibrinogen level was determined using a Clauss
technique (Fibromat, BioMerieux, Paris, France).
The von Willebrand factor was determined using an enzyme-
linked immunosorbent assay technique for the antigenicity (Asse-
rachrom vWF; Diagnostica Stago, Asnie`res, France) and ristoce-
tin-induced platelet aggregation for the activity (von Willebrand
reagent; Dade Behring, Paris, France).
Flow Cytometric Analysis
To study platelet activation, we measured the spontaneous expres-
sion of CD62P (P-selectin or granule membrane protein 140) on
the platelet membrane surface. Platelet activability was assessed
by measuring the membrane expression of glycoproteins (GPs)
IIb3 and Ib in the absence and presence of adenosine diphos-
phate (ADP) (Beckman Coulter). Ex vivo, diluted PRP (40 L)
was incubated in the absence or presence of ADP (25 mol/L), and
platelet activability was quantified with a FacScan flow cytometer
(Becton Dickinson, Mountain View, Calif). Saturating concentra-
tions of different monoclonal antibodies directly coupled with
fluorochromes were used: SZ2 directed against GP 1b, P2 di-
rected against GP IIb3 complex (Beckman Coulter), and mono-
clonal antibody anti–P-selectin (anti-CD62P, Becton Dickinson).
The results are expressed as a percentage of positive platelets for
CD62P expression or as the number of GP sites using calibration
beads (Byocytex, Marseille, France). Normal values from the
laboratory were previously recorded from 600 control subjects for
factor I levels, von Willebrand factor (antigen and activity), and
platelet integrins.
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PStatistical Analysis
The results are expressed as mean  SD or median (extremes).
Flow cytometric measurement of integrin expression was com-
pared using the Mann-Whitney U test, and correlation with aspirin




Two patients were female. The median age was 44.3 years
(16.6-58.6 years). Mechanical support was biventricular in
10 patients (5 had a left ventricular support only). The
median CPB duration was 162 minutes (96-339 minutes),
and the median duration of support was 72 days (28-360
days). Three patients died during VAD support. The first
patient died of sepsis, the second patient died of intracranial
hemorrhage, and the third patient died of device dysfunc-
tion.
Platelet Count and Platelet Volume
Figure 1 shows the platelet count and volume on weekly
follow-up. The platelet count steadily increased during the
first 2 postoperative weeks and remained stable after the
fourth postoperative week (laboratory control values are
150-400 giga/mm3 and 8-12 fl for platelet count and platelet
volume, respectively). A type II heparin-induced thrombo-
cytopenia developed in 1 patient the fourth week after
device implantation. Heparin was stopped and replaced by
antivitamin K therapy. Aspirin was maintained.
Resistance to Aspirin Treatment
Figure 2 represents platelet aggregation velocity in patients
treated with aspirin. The zero y axis value corresponds to
the absence of platelet aggregation (and aspirin efficacy).
The mean doses of aspirin administered per day (day of
Figure 1. Time course of platelet volume (fl) and platelet count
after external VAD implantation. (*P < .05 vs laboratory control
values; n  absolute number of patients.)blood collection for platelet ex vivo testing) were the fol-
The Journal of Thoracilowing: first week, 260  38 mg; second week, 249  90
mg; third week, 255  100 mg; fourth week, 250  149
mg; fifth week, 273  160 mg; and sixth week, 288  164
mg.
Aspirin resistance, as previously defined, was observed
in a total of 6 patients. These patients are represented in
Figure 2 by any value above the zero value of platelet
aggregation velocity at each weekly blood test.
Five of 6 patients responded to an increased daily dose of
aspirin. Three of 5 patients had a recurrence of this phe-
nomenon when the daily dose of aspirin was increased.
In 3 patients, aspirin resistance was observed from the
first week of treatment with aspirin after VAD implantation.
Inflammatory State: Endothelial Activation
Figure 3 shows the temporal trend of fibrinogen levels
significantly above laboratory control values (2-4 g/L) dur-
ing the entire postoperative course.
Figure 4 displays the temporal trend of circulating von
Willebrand factor (activity and antigenic determination)
during the postoperative course. These levels remained sig-
nificantly above laboratory control values (60%-100% von
Willebrand factor activity and 60%-100% antibody binding)
after implantation and during the entire study period.
Platelet Activation
The expression of P-selectin on the membrane surface of
platelets was present during the entire study period (Figure
5). The normal range value was 3000 to 6500 sites per
platelet.
Figure 6 shows the expression of GP IIb3 and GP Ib
during the postoperative course. The normal range values
were 24,000 to 38,000 and 10,500 to 19,000 sites per
Figure 2. Ex vivo platelet aggregation velocity in the presence of
AA (0.2 mg/mL) in patients receiving aspirin. Resistance to aspirin
treatment was defined as any persisting ex vivo platelet aggre-
gation induced by AA despite a daily administration of aspirin.platelet for GP IIb3 and GP Ib, respectively. After the
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first week, GP IIb3 expression remained within the nor-
mal range but closer to the lower limit. GP Ib expression
remained in the lower limits but closer to normal range
values. Ex vivo-induced externalization of GP IIb3 and
internalization of GP Ib in the presence of adenosine
remained within normal values during the entire postoper-
ative course (Figures 7 and 8) (normal range values are 26%
 11% for GP IIb3 externalization and 17%  9% for
GP Ib internalization).
No difference was observed in the expression of GP
IIb3 and GP Ib when comparing patients who displayed
some resistance to aspirin and other patients. No correlation
was observed between the daily aspirin dose and the ex-
Figure 3. Time course of fibrinogen levels after external VAD
implantation. Laboratory control values (dotted lines). (*P < .05 vs
laboratory control values; n  absolute number of patients.)
Figure 4. Time course of circulating von Willebrand factor anti-
gen and activity after external VAD implantation. Laboratory
control values (dotted lines). (*P < .05 and **P < .05: von
Willebrand factor [antigen and activity] vs laboratory control
values; n absolute number of patients.) v WFac; Von Willebrand
factor activity; v WFag, von Willebrand factor antigen.pression of integrin on platelet surface by flow cytometry.
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This study examined platelet activation and aggregation in
patients implanted with an external pulsatile VAD for pri-
mary cardiogenic shock. We observed a persisting platelet
activation profile and normal or reduced platelet activability
after implantation. We also observed a resistance to aspirin
in 26% of the patients who responded to increased doses of
aspirin up to 500 mg/d.
In healthy subjects, aspirin efficacy is observed with low
doses (100 mg/d), but with some individual variability.1,2
In patients with atherosclerotic disease, its efficacy is re-
duced and may necessitate higher daily doses to overcome
an erythrocyte promotion of platelet reactivity.4,12,13 After
Figure 5. Time course expression of P-selectin on platelet sur-
face membrane after external VAD implantation from flow cytom-
etry measurements. Laboratory control value is less than 2% of
platelets expressing this surface protein. (*P < .05 vs laboratory
control values; n  absolute number of patients.)
Figure 6. Time course expression of GPs IIb3 and Ib on
platelet surface membrane after external VAD implantation from
flow cytometry measurements. No difference was observed when
compared with laboratory control values (n absolute number of
patients). GP, Glycoprotein.CPB, thromboxane A2 synthesis persists at 70% to 54% of
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Pcontrol values after 5 and 10 days, respectively, despite a
daily oral intake of 100 mg of aspirin.3
We observed a persistent AA-induced platelet aggrega-
tion in the presence of AA in 26% of patients receiving at
least 250 mg of aspirin daily. Moreover, this so-called
aspirin resistance could occur a few weeks after surgery,
whereas previous platelet studies showed an ex vivo aspirin
efficacy in the same patient. The mechanism of this phe-
nomenon may be explained by an increased turnover of
platelets in the early postoperative weeks, as observed after
CPB. This increased turnover of platelets may overcome the
effect of aspirin on thromboxane A2 synthesis.3 An in-
creased turnover may be a possibility in our patients with
implanted VADs. In our study, we observed an increased
platelet volume with a decreased platelet count during the
early postoperative weeks after VAD implantation with
CPB.
Another mechanism of resistance to aspirin could be an
inflammatory-induced cyclooxygenase-2 isoform activity
that is less sensitive to aspirin acetylation.5 Indeed, a pro-
longed inflammatory reaction is observed in patients im-
planted with VADs. Cytokine levels such as interleukin-6
and interleukin-8 or complement fractions (C3a, C5a) are
increased several weeks after implantation.14,15 These mol-
ecules have also been reported to induce platelet activa-
tion.16 A persistent inflammatory state was also observed in
our patients, as expressed by elevated fibrinogen levels and
circulating von Willebrand factor values during the postop-
erative course.
Platelet activation studies measuring the membrane ex-
pression of P-selectin showed a persistent activation of
platelets during this prolonged period of support.17 In vitro,
the GP IIb3 complex has been reported to be selectively
degraded after prolonged ventricular assist.18 In our pa-
tients, integrin IIb3 and Ib expression on platelet sur-
face remained within normal values and may reflect a per-
sisting moderate platelet activation. No correlation was
found between the daily dose of aspirin and membrane
expression of these GPs, and no difference was observed
between the integrin expression in patients who displayed
resistance to aspirin and other patients. Membrane expres-
sion of integrin IIb3 has individual variations according
to gender or genetic polymorphism associated with different
aspirin sensitivity.19-21 This persistent platelet activated
state could be related to permanent activation from a path-
way other than the ADP pathway: Continuous thrombin
generation has been reported in patients implanted with
different VADs.15,22,23 Thrombin has a powerful effect on
platelet activation through specific protease-activated recep-
tor pathways (1 and 4) insensitive to aspirin.24-26
GP Ib is coupled with von Willebrand factor when
activated9,27 by high shear stress stimuli and is responsible
for platelet adhesion and activation. This pathway is poorly
The Journal of Thoracisensitive to aspirin.26,28 The platelet activation observed in
our patients could therefore be explained by high shear
stress in the presence of an artificial ventricle. High shear
stress could be developed by a high upstroke pattern on the
apex cardiogram in the artificial ventricle with reduced
inflow and outflow conduit diameters (14 mm diameter),
resulting in high conduit velocities. Moreover, the sub-
strates of these receptors (von Willebrand factor) remained
within high-range values during the 6 postoperative weeks,
indicating facilitated receptor-substrate interactions. These
mechanisms of platelet activation make the efficacy of
aspirin as an antiplatelet agent questionable despite the
observation of decreased thromboxane A2 production.
These patients are also characterized by a preserved
Figure 7. Time course externalization of GP IIb3 on platelet
surface membrane after ex vivo induction using ADP (25 mol/L)
(n  absolute number of patients). Laboratory control values
(dotted lines). GP, Glycoprotein.
Figure 8. Time course externalization of GP Ib on platelet sur-
face membrane after ex vivo induction using ADP (25 mol/L) (n
 absolute number of patients). Laboratory control values (dotted
lines). GP, Glycoprotein.platelet reactivity considering only GP IIb3 and GP Ib
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CSP(Figures 6 and 7), despite an initial increased turnover
associated with a continuous activation. The balance be-
tween enhanced platelet activation and reactivity may con-
tribute to the individual tendencies for thrombosis or bleed-
ing in patients with this type of VAD. Aspirin may favor the
balance toward a reduced platelet aggregation but requires
appropriate monitoring and adjusted doses to be biologi-
cally efficient.
References
1. Pappas JM, Westengard JC, Bulls JS. Population variability in the
effect of aspirin on platelet function. Implications for clinical trials and
therapy. Arch Pathol Lab Med. 1993;118:801-4.
2. Gum PA, Kottke-Marchant K, Poggio ED, Gurm H, Welsh PA,
Brooks L, et al. Profile and prevalence of aspirin resistance in patients
with cardiovascular disease. Am J Cardiol. 2001;88:230-5.
3. Zimmerman N, Kienzle P, Weber AA, Winter J, Gams E, Schro¨r K, et
al. Aspirin resistance after coronary artery bypass grafting. J Thorac
Cardiovasc Surg. 2001;121:982-4.
4. Valles J, Santos T, Aznar J, Osa A, Lago A, Cosin J, et al. Erythrocyte
promotion of platelet reactivity decrease the effectiveness of aspirin as
an antithrombotic therapeutic modality. Circulation. 1998;97:350-5.
5. Weber A-A, Zimmerman KC, Meyer-Kichrath J, Schro¨r K. Cycloox-
ygenase-2 in human platelets as a possible factor in aspirin resistance.
Lancet. 1999;353:900.
6. Baker LC, Davis WC, Autieri J, Watach MJ, Yamazaki K, Litwak P,
et al. Flow cytometric assays to detect platelet activation and aggre-
gation in device-implanted calves. J Biomed Mater Res. 1998;41:312-
21.
7. Abhrams CS, Ellison N, Budzynski AZ, Shattil SJ. Direct detection of
activated platelets and platelet-derived microparticles in humans.
Blood. 1990;88:1525-41.
8. Kamath S, Blann AD, Lip AHY. Platelet activation: assessment and
quantification. Eur Heart J. 2001;22:1561-71.
9. Goto S, Ikeda Y, Saldivar E, Ruggeri ZM. Distinct mechanisms of
platelet aggregation as a consequence of different flows conditions.
J Clin Invest. 1998;101:479-86.
10. Houel R, Moczar M, Clerin V, Loisance DY. Pseudointima in inflow
conduits of left ventricular assist devices. Ann Thorac Surg. 1999;68:
717-23.
11. El-Banayosy A, Arusoglu L, Kzner L, Tenderich G, Minami K, Inoue
K, et al. Novacor left ventricular assist system versus HeartMate
vented electric left ventricular assist system as a long term mechanical
circulatory support device in bridging patients: a prospective study.
J Thorac Cardiovasc Surg. 2000;119:581-7.12. Santos T, Valles J, Aznar J, Marcus AJ, Broekman MJ, Safier LB.
202 The Journal of Thoracic and Cardiovascular Surgery ● AuguProthrombotic effects of erythrocytes on platelet reactivity. Circula-
tion. 1997;95:63-8.
13. Helgason CM, Bolin KM, Hoff JA, Winkler SR, Mangat A, Tortori
KL, et al. Development of aspirin resistance in person with previous
ischemic stroke. Stroke. 1994;25:2331-6.
14. Corry DC, DeLucia A, Zhu H, Radcliffe RR, Brevetti GR, El-Khatib
H, et al. Time course of cytokine release and complement activation
after implantation of the HeartMate left ventricular assist device.
ASAIO J. 1998;44:M347-51.
15. Wilhem CR, Ristish J, Kormos RL, Wagner WR. Monocyte tissue
factor expression and ongoing complement generation in ventricular
assist device patients. Ann Thorac Surg. 1998;65:1071-6.
16. Lumadue JA, Lanzkron SM, Kennedy SD, Khul DT, Kikkler TS.
Cytokine induction of platelet activation. Am J Clin Pathol. 1996;106:
795-8.
17. Matsubayashi H, Fastenau DR, McIntyre JA. Changes in platelet
activation associated with left ventricular assist system placement.
J Heart Lung Transplant. 2000;19:462-8.
18. Serna DL, King BO, Huh J, Jalal R, Tran L, Chen JC. Evidence for
selective degradation of platelet GP IIb/IIIa complex after prolonged in
vitro ventricular assist. J Invest Med. 1998;46:279-83.
19. Weiss EJ, Bray PF, Tayback M. A polymorphism of platelet glycopro-
tein receptor as an inherited risk factor for coronary thrombosis.
N Engl J Med. 1996;334:1090-4.
20. Faraday N, Goldschmidt-Clermont P, Bray PF. Gender differences in
platelet GPIIb-IIIa activation. Thromb Haemost. 1997;77:748-54.
21. Cooke GE, Bray PF, Hamlington JD, Pham DM, Goldsmidt-Clermont
PJ. PIA2 polymorphism and efficacy of aspirin. Lancet. 2001;351:
1253.
22. Spanier T, Oz M, Levin H, Weinberg A, Stamatis K, Stern D, et al.
Activation of coagulation and fibrinolytic pathways in patients with
left ventricular assist devices. J Thorac Cardiovasc Surg. 1996;112:
1090-7.
23. Koster A, Loebe M, Hanse R, Potapov EV, Noon GP, Kuppe H, et al.
Alterations in coagulation after implantation of a pulsatile Novacor
LVAD and the axial flow Micromed DeBackey LVAD. Ann Thorac
Surg. 2000;70:533-7.
24. Kahn ML, Zheng Y, Huang W, Bigornia V, Zeng D, Moff S, et al. A
dual thrombin receptor system for platelet activation. Nature. 1998;
394:690-4.
25. Brass S. Platelets and proteases. Nature. 2001;413:26-7.
26. Parker RI, Gralnick HR. Effect of aspirin on platelet-von Willebrand
factor surface expression on thrombin and ADP-stimulated platelets.
Blood. 1989;74:2016-21.
27. Kroll MH, Hellums JD, McIntire LV, Shafer AI, Moake JL. Platelets
and shear stress. Blood. 1996;88:1525-41.
28. Maalej N, Folts JD. Increased shear stress overcome the antithrom-
botic platelet inhibitory effect of aspirin in stenosed dog coronary
artery. Circulation. 1996;93:1201-5.
st 2004
